**Patient Discharge Summary**

**Patient Details:**  
- **Name:** [Patient Name]  
- **Age:** [Patient Age]  
- **Sex:** [Patient Sex]  
- **Hospital ID:** [Hospital Identification Number]  
- **Admission Date:** September 21, 2023  
- **Discharge Date:** September 28, 2023  
- **Admitting Physician:** Dr. [Admitting Physician Name]  
- **Department:** Infectious Diseases Unit  

**Chief Complaint:** The patient presented to the emergency department on September 21, 2023, with complaints of high fever, severe headache, muscle aches, and coughing that started approximately two days prior.

**History of Present Illness:** The patient's symptoms began mildly and progressively worsened over the next 48 hours, prompting hospital admission. They reported no recent travel or known exposure to individuals with similar symptoms. The patient has a medical history of asthma, which has been well-controlled with medication.

**Physical Examination:** Upon admission, the patient was febrile with a temperature of 102.2°F (39°C), had a pulse rate of 98 beats per minute, a respiratory rate of 20 breaths per minute, and a blood pressure of 120/80 mmHg. Examination revealed diffuse wheezing on auscultation, likely exacerbated by the patient's underlying asthma.

**Diagnostic Findings:**  
- **Rapid Antigen Test:** Conducted on September 21, 2023, came back positive for Influenza A.
- **RT-PCR Test:** Confirmed the presence of Influenza A subtype H3N2 on September 22, 2023.
- **Chest X-Ray:** Performed on September 22, 2023, indicated clear lungs with no evidence of pneumonia.
- **Pulse Oximetry:** Showed an oxygen saturation of 95% on room air.

**Hospital Course:**  
- The patient was admitted to the Infectious Diseases Unit for close monitoring due to their history of asthma and the risk of complications.  
- **Medication:** The patient was started on Oseltamivir 75 mg orally twice a day for five days, beginning on September 21, 2023. Due to the patient's asthma, Zanamivir was avoided to prevent potential bronchospasm.  
- **Supportive Care:** Included administration of IV fluids for hydration and acetaminophen for fever and myalgias. The patient's asthma was managed with their regular inhaler, with no need for corticosteroid escalation.  
- **Response to Treatment:** The patient showed significant improvement. Fever resolved by September 24, 2023, and respiratory symptoms improved steadily over the next few days.  
- **Discharge Planning:** The patient was counseled on the importance of rest, hydration, and completing the course of Oseltamivir. Instructions were provided on symptom management at home and criteria for seeking further medical care.

**Discharge Medications:**  
- **Oseltamivir 75 mg orally twice a day:** The patient is to complete a 5-day course, with the last dose to be taken on September 26, 2023.  
- **Inhaler (as per the patient's asthma management plan)**  

**Follow-Up:**  
- The patient is scheduled for a follow-up visit with Dr. [Admitting Physician Name] in the Infectious Diseases Unit on October 5, 2023.  
- An additional follow-up with the patient's primary care physician and asthma specialist is recommended within two weeks to ensure complete recovery and optimal management of asthma.

**Patient Education:**  
- The patient was educated on the signs of potential complications, including shortness of breath, chest pain, or worsening of symptoms, and advised to seek immediate medical attention if these occur.  
- Influenza vaccination was strongly recommended for the next influenza season to reduce the risk of future infection.

**Summary and Recommendations:**  
The patient, [Patient Name], was admitted with Influenza A and has responded well to treatment with Oseltamivir and supportive care for their symptoms. Given the patient's underlying asthma, close monitoring was warranted during their stay. Upon discharge, the patient has been advised to complete their antiviral course, follow their asthma management plan, and seek immediate care if symptoms worsen or complications arise. Vaccination against influenza in the future is highly recommended.

**Prepared by:**  
[Doctor's Name], MD  
[Department]  
[Date]